SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Trossaërt M.)
 

Sökning: WFRF:(Trossaërt M.) > European retrospect...

European retrospective study of real-life haemophilia treatment

Berntorp, E. (författare)
Lund University,Lunds universitet,Klinisk koagulationsmedicin, Malmö,Forskargrupper vid Lunds universitet,Clinical Coagulation, Malmö,Lund University Research Groups
Dolan, G. (författare)
Guy's and St Thomas' NHS Foundation Trust
Hay, C. (författare)
Manchester Royal Infirmary
visa fler...
Linari, S. (författare)
Careggi University Hospital
Santagostino, E. (författare)
Maggiore Hospital Policlinico
Tosetto, A. (författare)
Castaman, G. (författare)
Careggi University Hospital
Álvarez-Román, Mt (författare)
University Hospital La Paz
Parra Lopez, R. (författare)
Vall d'Hebron University Hospital
Oldenburg, J. (författare)
University Hospital Bonn
Albert, T. (författare)
University Hospital Bonn
Scholz, U. (författare)
Center of Haemostasis Leipzig
Holmström, M. (författare)
Karolinska Institutet,Karolinska Institute
Schved, J. F. (författare)
Hôpital Saint Eloi
Trossaërt, M. (författare)
Nantes University Hospital
Hermans, C. (författare)
Saint-Luc University Hospital
Boban, A. (författare)
Saint-Luc University Hospital
Ludlam, C. (författare)
University of Edinburgh
Lethagen, S. (författare)
University of Copenhagen,Swedish Orphan Biovitrum
visa färre...
 (creator_code:org_t)
2016-10-20
2017
Engelska.
Ingår i: Haemophilia. - : Wiley. - 1351-8216. ; 23:1, s. 105-114
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Introduction: Haemophilia treatment varies significantly between individuals, countries and regions and details of bleed rates, factor consumption and injection frequency are often not available. Aim: To provide an overview of the FVIII/FIX treatment practice and outcome for patients with haemophilia A (HA) or haemophilia B (HB) across Europe. Methods: Non-interventional, 12-month retrospective study where anonymized data were retrieved from haemophilia centres/registers in Belgium, France, Germany, Italy, Spain, Sweden and the United Kingdom. Male patients (all ages) receiving coagulation factor treatment 24 months prior to the study, with basal FVIII/FIX levels ≤5 IU dL-1, without inhibitors, were included. Data were summarized descriptively. Results: In total, 1346 patients with HA and 312 with HB were included in the analysis; 75% and 57% had severe disease (FVIII/FIX < 1 IU dL-1) respectively. Prophylaxis was most common for severe haemophilia, especially for children, whereas on-demand treatment was more common for moderate haemophilia in most countries. The mean (SD) prescribed prophylactic treatment ranged from 67.9 (30.4) to 108.4 (78.1) (HA) and 32.3 (10.2) to 97.7 (32.1) (HB) IU kg-1 per week, across countries. Most patients on prophylaxis were treated ≥3 times/week (HA) or two times/week (HB). The median annual bleeding rate (ABR) for patients on prophylaxis ranged from 1.0 to 4.0 for severe HA, and from 1.0 to 6.0 for severe HB, while those with moderate haemophilia generally had slightly higher ABRs. Median ABRs for on-demand-treated severe HA ranged from 4.5 to 18.0, and for HB, 1.5 to 14.0. Conclusion: Treatment practice varied greatly between centres and countries and patients treated on-demand and prophylactically both experienced bleeds, emphasizing the need for further optimization of care.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Hematologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Hematology (hsv//eng)

Nyckelord

Factor IX
Factor VIII
Haemophilia A
Haemophilia B
Retrospective study
Treatment

Publikations- och innehållstyp

art (ämneskategori)
ref (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy